Transcriptional Dysregulation of MYC Reveals Common Enhancer-Docking Mechanism
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Transcriptional dysregulation of the MYC oncogene is among the most frequent events in aggressive tumor cells, and this is generally accomplished by acquisition of a super-enhancer somewhere within the 2.8 Mb TAD where MYC resides. We find that these diverse cancer-specific super-enhancers, differing in size and location, interact with the MYC gene through a common and conserved CTCF binding site located 2 kb upstream of the MYC promoter. Genetic perturbation of this enhancer-docking site in tumor cells reduces CTCF binding, super-enhancer interaction, MYC gene expression, and cell proliferation. CTCF binding is highly sensitive to DNA methylation, and this enhancer-docking site, which is hypomethylated in diverse cancers, can be inactivated through epigenetic editing with dCas9-DNMT. Similar enhancer-docking sites occur at other genes, including genes with prominent roles in multiple cancers, suggesting a mechanism by which tumor cell oncogenes can generally hijack enhancers. These results provide insights into mechanisms that allow a single target gene to be regulated by diverse enhancer elements in different cell types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
A 3D Map of the Human Genome at Kilobase Resolution Reveals Principles of Chromatin Looping
Rao, S. S. P., Huntley, M. H., Durand, N. C., Stamenova, E. K., Bochkov, I. D., Robinson, J. T., Sanborn, A. L., Machol, I., Omer, A. D., Lander, E. S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.021 · Cited by 9,212
Topological domains in mammalian genomes identified by analysis of chromatin interactions
Dixon, J. R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J. S., & Ren, B. (2012) · Nature · doi:10.1038/nature11082 · Cited by 6,829 · cited 3×
“CTCF does not generally occupy enhancer and promoter elements (Cuddapah et al., 2009; Dixon et al., 2012; Dowen et al., 2014; Handoko et al., 2011; Ji et al., 2016; Kim et al., 2007; Phillips-Cremins et al., 2013; Rao et al., 2014; Rubio et al., 2008; Tang et al., 2015).”
BackgroundSuper-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662 · cited 5×
“Dysregulation of MYC is often achieved through the formation of large tumor-specific superenhancers in the region surrounding the MYC gene (Chapuy et al., 2013; Fulco et al., 2016; Herranz et al., 2014; Hnisz et al., 2013; Lin et al., 2016; Liu et al., 2015; Lovén et al., 2013; Shi et al., 2013; Whyte et al., 2013; Zh…”
BackgroundInfluentialSelf-citationDang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961 · cited 5×
“Previous studies have established that tumor cells acquire tumor-specific super-enhancers at various sites throughout the MYC locus (Figures 1A and S1A) (Bradner et al., 2017; Chapuy et al., 2013; Gabay et al., 2014; Gröschel et al., 2014; Herranz et al., 2014; Hnisz et al., 2013; Lin et al., 2016; Lovén et al., 2013;…”
BackgroundInfluentialSelf-citationSpatial partitioning of the regulatory landscape of the X-inactivation centre
Nora, E. P., Lajoie, B. R., Schulz, E. G., Giorgetti, L., Okamoto, I., Servant, N., Piolot, T., van Berkum, N. L., Meisig, J., Sedat, J., et al. (2012) · Nature · doi:10.1038/nature11049 · Cited by 2,895 · cited 2×
“…tend to insulate enhancers and genes within the CTCF-CTCF loops from elements outside those loops (Dixon et al., 2012; Dowen et al., 2014; Franke et al., 2016; Hnisz et al., 2016a, 2016b; Ji et al., 2016; Narendra et al., 2015; Nora et al., 2012; Phillips-Cremins et al., 2013; Rao et al., 2014).”
BackgroundMethylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene
Bell, A. C., & Felsenfeld, G. (2000) · Nature · doi:10.1038/35013100 · Cited by 1,746 · cited 2×
“Loss of MYC Expression with Methylation of Enhancer-Docking Site CTCF binding is abrogated when its sequence motif is methylated (Bell and Felsenfeld, 2000; Maurano et al., 2015), and the MYC enhancer-docking site occurs within a CpG island that is consistently hypomethylated in different tumor…”
BackgroundNora, E. P., Goloborodko, A., Valton, A.-L., Gibcus, J. H., Uebersohn, A., Abdennur, N., Dekker, J., Mirny, L. A., & Bruneau, B. G. (2017) · Cell · doi:10.1016/j.cell.2017.05.004 · Cited by 1,709 · cited 4×
“CTCF Enhancer-Docking Sites at Additional Genes Previous genomic studies have noted that CTCF might engender enhancer-promoter interactions at a minority of genes (Banani et al., 2017; Nora et al., 2017; Splinter et al., 2006; Zuin et al., 2014).”
BackgroundInfluentialLi, G., Ruan, X., Auerbach, R. K., Sandhu, K. S., Zheng, M., Wang, P., Poh, H. M., Goh, Y., Lim, J., Zhang, J., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.014 · Cited by 1,232 · cited 1×
“For MCF7, Pol II ChIA-PET interactions with an origami score of at least 0.9 are shown as purple arcs; the insulated neighborhood spanning interactions from CTCF ChIA-PET data are shown in blue (data from ENCODE and Li et al., 2012).”
MethodInfluential
Cited by
The chromatin accessibility landscape of primary human cancers
Corces, M. R., Granja, J. M., Shams, S., Louie, B. H., Seoane, J. A., Zhou, W., Silva, T. C., Groeneveld, C., Wong, C. K., Cho, S. W., et al. (2018) · Science · doi:10.1126/science.aav1898 · Cited by 1,230
“MYC is embedded in a region with multiple DNA regulatory elements and noncoding transcripts that regulate MYC in a tissue-specific fashion (19).”
BackgroundAdvances in Targeting ‘Undruggable’ transcription Factors With Small Molecules
Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409
Schulte-Sasse, R., Budach, S., Hnisz, D., & Marsico, A. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-021-00325-y · Cited by 256
Self-citationInterferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation
Yu, M., Peng, Z., Qin, M., Liu, Y., Wang, J., Zhang, C., Lin, J., Dong, T., Wang, L., Li, S., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.010 · Cited by 250
Cai, J., Yi, M., Tan, Y., Li, X., Li, G., Zeng, Z., Xiong, W., & Xiang, B. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01995-7 · Cited by 215
Enhancer selectivity in space and time: from enhancer–promoter interactions to promoter activation
Yang, J. H., & Hansen, A. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00710-6 · Cited by 191
“P pairs with proximal CTCF binding only at the promoter include the Vcan gene with the Xrcc4/Tmem167 promoter acting as an enhancer about 350 kb downstream in mouse NPCs 93 and the MYC gene with the MYC endometrial carcinoma super-enhancer located 800 kb downstream in Ishikawa cells 218,219 (Fig.”
InfluentialEnhancer release and retargeting activates disease-susceptibility genes
Oh, S., Shao, J., Mitra, J., Xiong, F., D’Antonio, M., Wang, R., Garcia-Bassets, I., Ma, Q., Zhu, X., Lee, J.-H., et al. (2021) · Nature · doi:10.1038/s41586-021-03577-1 · Cited by 148
BET inhibition disrupts transcription but retains enhancer-promoter contact
Crump, N. T., Ballabio, E., Godfrey, L., Thorne, R., Repapi, E., Kerry, J., Tapia, M., Hua, P., Lagerholm, C., Filippakopoulos, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20400-z · Cited by 123
Chakraborty, S., Kopitchinski, N., Zuo, Z., Eraso, A., Awasthi, P., Chari, R., Mitra, A., Tobias, I. C., Moorthy, S. D., Dale, R. K., et al. (2023) · Nature Genetics · doi:10.1038/s41588-022-01295-6 · Cited by 120
Chen, L.-F., Long, H. K., Park, M., Swigut, T., Boettiger, A. N., & Wysocka, J. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.03.009 · Cited by 66
Taylor, T., Sikorska, N., Shchuka, V. M., Chahar, S., Ji, C., Macpherson, N. N., Moorthy, S. D., de Kort, M. A. C., Mullany, S., Khader, N., et al. (2022) · Genes & Development · doi:10.1101/gad.349489.122 · Cited by 45
The c-Myc/AKT1/TBX3 Axis Is Important to Target in the Treatment of Embryonal Rhabdomyosarcoma
Sims, D., Maranyane, H. M., Damerell, V., Govender, D., Isaacs, A. W., Peres, J., & Prince, S. (2020) · Cancers · doi:10.3390/cancers12020501 · Cited by 13
CREaTor: zero-shot cis-regulatory pattern modeling with attention mechanisms
Li, Y., Ju, F., Chen, Z., Qu, Y., Xia, H., He, L., Wu, L., Zhu, J., Shao, B., & Deng, P. (2023) · Genome Biology · doi:10.1186/s13059-023-03103-8 · Cited by 12
“Lastly, we examined if our model recovered regulators of the oncogenic gene MYC (chr8: 127,735,434–127,742,951). cCREs of MYC disperse along genomic sequences to as far as 2 Mb downstream MYC TSS and active MYC regulators in K562 were identified by previous studies with various approaches [39–41].”
BackgroundLive-cell imaging of enhancer-promoter dynamics reveals transient contact-driven gene activation
Yang, J. H., Pinholt, H. D., Toppen, J., Huseyin, M. K., Jusuf, J. M., Katsifis, C. C., Kæstel-Hansen, J., Mirny, L. A., Zechner, C., & Hansen, A. S. (2026) · doi:10.64898/2026.06.21.733446 · Cited by 3
Metadata
- Authors
- Schuijers, J., Manteiga, J. C., Weintraub, A. S., Day, D. S., Zamudio, A. V., Hnisz, D., Lee, T. I., & Young, R. A.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 23
- Issue
- 2
- Pages
- 349-360
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2796842840
- Cited by
- 233
- References
- 37
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.